Immune Mechanisms of Viral Control (R21)
The summary for the Immune Mechanisms of Viral Control (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Immune Mechanisms of Viral Control (R21): -Purpose. This Funding Opportunity Announcement (FOA) will support the first phase of a two-stage program to expand understanding of the underlying mechanisms of immunity to viral infection and vaccination. The first phase to be awarded in fiscal year 2007 will use R21 exploratory/developmental grants to address key questions related to viral immunity. The second phase, planned for award in fiscal year 2009, will support a substantially larger effort involving collaborative teams funded through U01 and U19 single and multiple project cooperative agreement grants. The overarching goal is to address key questions in viral immunity and the immunological basis of vaccination. While NIAID expects R21 awardees to generate preliminary data and establish collaborations that will facilitate highly competitive applications for the second phase of the program, R21 funding under the first phase of the program will not be a prerequisite for applications under future research solicitations. -Mechanism of Support. This FOA will utilize the R21 grant mechanism. -Funds Available and Anticipated Number of Awards. The total amount to be awarded is $4 million. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
|Federal Grant Title:||Immune Mechanisms of Viral Control (R21)|
|Federal Agency Name:||National Institutes of Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-AI-07-008|
|Type of Funding:||Grant|
|CFDA Descriptions:||Allergy, Immunology and Transplantation Research 93.856 Microbiology and Infectious Diseases Research|
|Current Application Deadline:||No deadline provided|
|Original Application Deadline:||Mar 30, 2007|
|Posted Date:||Dec 12, 2006|
|Creation Date:||Dec 12, 2006|
|Archive Date:||Apr 29, 2007|
|Total Program Funding:||$4,000,000|
|Maximum Federal Grant Award:|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Special district governments State governments Private institutions of higher education Independent school districts Public and State controlled institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) For profit organizations other than small businesses
- Additional Information on Eligibility
- Foreign institutions are not eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- More Grants from the National Institutes of Health
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
- • New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...